Table 1 Presentation of the major studies reporting the efficacy of perampanel in children and adolescents with focal seizures
Authors, year | Study type | N of children/adolescents (age) | Perampanel dosage | Responder rates | Seizure reduction |
|---|---|---|---|---|---|
French et al., 2012 | multicenter, double-blind, placebo-controlled trial (study 304) | 143a (12-17 y) | 8-12 mg/day | 2 mg: 4.8% | 2 mg: +12.8% |
4 mg: 23.1% | 4 mg: 23.9% | ||||
8 mg: 40.9% | 8 mg: 34.8% | ||||
12 mg: 45% | 12 mg: 35.6% | ||||
placebo: 22.2% | placebo: 18.0% | ||||
Krauss et al., 2012 | multicenter, double-blind, placebo-controlled trial (study 306) | 2-8 mg/day | |||
French et al., 2013 | multicenter, double-blind, placebo-controlled trial (study 305) | 8-12 mg/day | |||
Krauss et al., 2013 | Extension study for patients completing the double-blind phase of the three previous phase III trials (study 307) | 8-12 mg/day | 27.3% to 60.0% in adolescents randomized to placebo and switched to perampanel | 35.8% for adolescents switched from placebo to perampanel | |
40.9% to 54.8% in adolescents receiving perampanel throughout the study | 40.9% in adolescents treated with perampanel in both the core and extension studies | ||||
Birò et al., 2015 | multicenter, observational, retrospective survey | 36c (2-17 y) | 2-12 mg/day | 33% | NR |
Lagae et al., 2016 | multicenter, randomized, double-blind, placebo-controlled, parallel-group study | 133b (12-17 y) | 8-12 mg/day | Perampanel: 59% | Perampanel: 58% |
Placebo: 37% | Placebo: 24% |